HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase

  • Nature. 2011 Nov 6;480(7377):379-82. doi: 10.1038/nature10623.
David C Goldstone  1 ,  Valerie Ennis-Adeniran ,  Joseph J Hedden ,  Harriet C T Groom ,  Gillian I Rice ,  Evangelos Christodoulou ,  Philip A Walker ,  Geoff Kelly ,  Lesley F Haire ,  Melvyn W Yap ,  Luiz Pedro S de Carvalho ,  Jonathan P Stoye ,  Yanick J Crow ,  Ian A Taylor ,  Michelle Webb
Affiliations
  • 1. Division of Molecular Structure, MRC National Institute for Medical Research, London NW7 1AA, UK.
Abstract

SAMHD1, an analogue of the murine interferon (IFN)-γ-induced gene Mg11 (ref. 1), has recently been identified as a human immunodeficiency virus-1 (HIV-1) restriction factor that blocks early-stage virus replication in dendritic and other myeloid cells and is the target of the lentiviral protein Vpx, which can relieve HIV-1 restriction. SAMHD1 is also associated with Aicardi-Goutières syndrome (AGS), an inflammatory encephalopathy characterized by chronic cerebrospinal fluid lymphocytosis and elevated levels of the Antiviral cytokine IFN-α. The pathology associated with AGS resembles congenital Viral Infection, such as transplacentally acquired HIV. Here we show that human SAMHD1 is a potent dGTP-stimulated triphosphohydrolase that converts deoxynucleoside triphosphates to the constituent deoxynucleoside and inorganic triphosphate. The crystal structure of the catalytic core of SAMHD1 reveals that the protein is dimeric and indicates a molecular basis for dGTP stimulation of catalytic activity against dNTPs. We propose that SAMHD1, which is highly expressed in dendritic cells, restricts HIV-1 replication by hydrolysing the majority of cellular dNTPs, thus inhibiting reverse transcription and viral complementary DNA (cDNA) synthesis.